Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

April 23, 2007 07:59 ET

Mistral Pharma to Present at BioFinance 2007

MONTREAL, QUEBEC--(CCNMatthews - April 23, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that it will be a presenter at the BIOFINANCE 2007 conference at the Toronto Marriott Eaton Center. This presentation will be given by Mr. Bertrand Bolduc, President and Chief Executive Officer of Mistral Pharma on April 25, 2007 in the Trinity III room at 3:30 p.m. (Toronto time).

"This is an excellent opportunity for us to update the financial community on our developments, including the recently announced acquisition of CuraMedica" commented Bertrand Bolduc. "Mistral has evolved quite significantly in the last year and we look forward to present our vision of Mistral's future" he added.

About BioFinance

BioFinance 2007 is the Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia. For more information visit the BioFinance website at www.biofinance.ca.

About Mistral Pharma Inc.

Mistral Pharma is a pharmaceutical product development and drug delivery company and its first two branded products, MIST-B01 & B02, showed positive results at their respective first pilot clinical trials. Mistral is also working on other control-delivery branded products. Mistral positions itself as a development partner for specialty pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information